Ischemic Digital Ulcers Affect Hand Disability and Pain in Systemic Sclerosis

Objective. Ischemic digital ulcers (DU) are frequent and severe complications of systemic sclerosis (SSc). The purpose of our study was to assess the effect of DU on hand disability and pain in patients with SSc. Methods. The Evaluation of the Impact of Recurrent Ischemic DU on Hand Disability in Patients with SSc (ECLIPSE) is a prospective, multicenter, noninterventional study with a 2-year followup. Patients with SSc who experienced at least 1 DU in the previous year and received bosentan therapy were included between October 2009 and March 2011. This cohort is described at the time of inclusion. Results. There were 190 patients (132 females) from 53 centers. Mean age ± SD was 43 ± 15 years at SSc diagnosis and 53 ± 15 years at inclusion. In 105 patients (56.2%), DU were the first non-Raynaud symptoms of SSc. The mean time interval between the occurrence of Raynaud phenomenon and the first DU episode was 6.6 ± 9.1 years. The mean numbers of active DU and fingers affected per patient for both hands were 2.3 ± 1.8 and 2.2 ± 1.6, respectively. Presence of active DU at inclusion was significantly associated with pain and impaired hand function: Visual Analog Scale for pain (0 to 10) was 6.2 ± 2.6 versus 2.5 ± 2.4 (p < 0.0001) and Cochin Hand Function Scale for hand disability (0 to 90) was 38 ± 20 versus 25 ± 19 (p < 0.0001), respectively. Conclusion. DU represent a major sign of SSc, often affecting multiple fingers and both hands. They are significantly associated with pain and hand disability.

[1]  D. Jayne,et al.  Summary of product characteristics , 2016 .

[2]  M. Silkey,et al.  Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry , 2012, Annals of the rheumatic diseases.

[3]  M. Matucci-Cerinic,et al.  Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. , 2011, Autoimmunity reviews.

[4]  L. Mouthon,et al.  Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers , 2011, Arthritis care & research.

[5]  M. Baron,et al.  Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry , 2011, Arthritis care & research.

[6]  M. Matucci-Cerinic,et al.  Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.

[7]  E. Hachulla,et al.  Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinérAIR-Sclérodermie) , 2009, The Journal of Rheumatology.

[8]  M. Revel,et al.  Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis , 2009, Annals of the rheumatic diseases.

[9]  R. Landewé,et al.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) , 2009, Annals of the rheumatic diseases.

[10]  E. Hachulla,et al.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. , 2007, The Journal of rheumatology.

[11]  M. Revel,et al.  Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. , 2007, Arthritis and rheumatism.

[12]  C. Denton,et al.  Digital ulcers: overt vascular disease in systemic sclerosis. , 2006, Rheumatology.

[13]  O. Chassany,et al.  Validation of French version of the Scleroderma Health Assessment Questionnaire (SSc HAQ) , 2005, Clinical Rheumatology.

[14]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[15]  J. Poole,et al.  Reliability and validity of the Duruoz Hand Index in persons with systemic sclerosis (scleroderma). , 2004, Arthritis and rheumatism.

[16]  Richard W. Martin,et al.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.

[17]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[18]  T. Perneger,et al.  The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. , 1998, Journal of clinical epidemiology.

[19]  J Fermanian,et al.  Development and validation of a rheumatoid hand functional disability scale that assesses functional handicap. , 1996, The Journal of rheumatology.

[20]  P Tugwell,et al.  The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. , 1987, The Journal of rheumatology.

[21]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[22]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[23]  N Rowell,et al.  Systemic sclerosis. , 1968, British medical journal.

[24]  J. Marks,et al.  [Ulcers]. , 1986, Phlebologie.

[25]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[26]  G. Burmester,et al.  Concise Report , 2022 .